Alzheimer's disease and mild cognitive impairment.

[1]  R. A. Wallis,et al.  Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. , 2008, Brain : a journal of neurology.

[2]  D. Galasko,et al.  Safety, Tolerability, Pharmacokinetics, and Aβ Levels After Short-term Administration of R-flurbiprofen in Healthy Elderly Individuals , 2007, Alzheimer disease and associated disorders.

[3]  Bruce L. Miller,et al.  Appendix B: Practice parameter: Diagnosis of dementia (an evidence-based review): Report of the quality standards subcommittee of the American academy neurology , 2007 .

[4]  M. Mesulam,et al.  Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's disease , 2007, Neurobiology of Aging.

[5]  A. Stefani,et al.  CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment , 2006, Journal of the Neurological Sciences.

[6]  P. Thompson,et al.  PET of brain amyloid and tau in mild cognitive impairment. , 2006, The New England journal of medicine.

[7]  H. Engler,et al.  Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. , 2006, Brain : a journal of neurology.

[8]  Julie C Price,et al.  Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. , 2006, Brain : a journal of neurology.

[9]  Colin L Masters,et al.  Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Abeta amyloid pathway. , 2006, Brain : a journal of neurology.

[10]  H. Soininen,et al.  CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. , 2006, Brain : a journal of neurology.

[11]  Keith A. Johnson,et al.  Amyloid imaging of alzheimer’s disease using pittsburgh compound B , 2006, Current Neurology and Neuroscience Reports.

[12]  Daniel Weintraub,et al.  Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. , 2006, The New England journal of medicine.

[13]  J. Helpern,et al.  Quantitative MR imaging in Alzheimer disease. , 2006, Radiology.

[14]  A. Wallin,et al.  Associations between white matter lesions, cerebrovascular risk factors, and low CSF Aβ42 , 2006, Neurology.

[15]  R. Petersen,et al.  Postmenopausal Estrogen Therapy and Alzheimer Disease: Overall Negative Findings , 2006, Alzheimer disease and associated disorders.

[16]  T. Iwatsubo,et al.  Naphthyl and coumarinyl biarylpiperazine derivatives as highly potent human beta-secretase inhibitors. Design, synthesis, and enzymatic BACE-1 and cell assays. , 2006, Journal of medicinal chemistry.

[17]  E. Tangalos,et al.  Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. , 2006, Archives of neurology.

[18]  E. Tangalos,et al.  Neuropathologic features of amnestic mild cognitive impairment. , 2006, Archives of neurology.

[19]  H. Vinters.  Neuropathology of amnestic mild cognitive impairment. , 2006, Archives of neurology.

[20]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[21]  Philip S. Insel,et al.  Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[22]  Robert A. Dean,et al.  Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease , 2006, Neurology.

[23]  J. Avorn,et al.  Risk of death in elderly users of conventional vs. atypical antipsychotic medications. , 2005, The New England journal of medicine.

[24]  Gunhild Waldemar,et al.  Evidence-based Evaluation of Magnetic Resonance Imaging as a Diagnostic Tool in Dementia Workup , 2005, Topics in magnetic resonance imaging : TMRI.

[25]  B. Winblad,et al.  Clinical trials in mild cognitive impairment: lessons for the future , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[26]  Lars Bäckman,et al.  Cognitive impairment in preclinical Alzheimer's disease: a meta-analysis. , 2005, Neuropsychology.

[27]  D. Bennett,et al.  Vitamin E and donepezil for the treatment of mild cognitive impairment. , 2005, The New England journal of medicine.

[28]  L. Thal,et al.  A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment , 2005, Neuropsychopharmacology.

[29]  Nick C Fox,et al.  Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.

[30]  W. Stalman,et al.  Economic evaluation of donepezil in moderate to severe Alzheimer disease , 2005, Neurology.

[31]  Nick C Fox,et al.  Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease , 2005, Neurology.

[32]  J. Cummings,et al.  The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.

[33]  J. Schneider,et al.  Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions , 2005, Neurology.

[34]  S. Wagner,et al.  Reductions in β-amyloid concentrations in vivo by the γ-secretase inhibitors BMS-289948 and BMS-299897 , 2005 .

[35]  E. Masliah,et al.  Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease , 2005, Neurology.

[36]  Roberto Pastor-Barriuso,et al.  Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality , 2005, Annals of Internal Medicine.

[37]  E G Tangalos,et al.  1H MR spectroscopy in common dementias , 2004, Neurology.

[38]  Eric J Topol,et al.  Failing the public health--rofecoxib, Merck, and the FDA. , 2004, The New England journal of medicine.

[39]  H. Möller,et al.  Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer’s disease , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[40]  R. Petersen.  Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.

[41]  Agneta Nordberg,et al.  PET imaging of amyloid in Alzheimer's disease , 2004, The Lancet Neurology.

[42]  C. Jack,et al.  Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.

[43]  J. Raftery,et al.  Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial , 2004, The Lancet.

[44]  JoAnn E Manson,et al.  Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. , 2004, JAMA.

[45]  M. Mesulam,et al.  Cholinergic nucleus basalis tauopathy emerges early in the aging‐MCI‐AD continuum , 2004, Annals of neurology.

[46]  P. Scheltens,et al.  Amyloid β(1–42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease , 2004, Neurology.

[47]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[48]  Charles DeCarli,et al.  Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? , 2003, Archives of neurology.

[49]  John Breitner,et al.  Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. , 2003, Archives of neurology.

[50]  S. Weggen,et al.  Evidence That Nonsteroidal Anti-inflammatory Drugs Decrease Amyloid β42 Production by Direct Modulation of γ-Secretase Activity* , 2003, Journal of Biological Chemistry.

[51]  Pritam Das,et al.  NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo , 2003 .

[52]  B. Dubois,et al.  Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization , 2003, Neurology.

[53]  K. Jellinger,et al.  Mild Cognitive Impairment. Aging to Alzheimer's disease , 2003 .

[54]  K. Davis,et al.  Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. , 2003, JAMA.

[55]  J. Manson,et al.  Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. , 2003, JAMA.

[56]  Robert B Wallace,et al.  Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. , 2003, JAMA.

[57]  Clifford R Jack,et al.  Neuroimaging in Alzheimer disease: an evidence-based review. , 2003, Neuroimaging clinics of North America.

[58]  H. Arai,et al.  CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects , 2002, Neurology.

[59]  H. Möller,et al.  Human antibodies against amyloid β peptide: A potential treatment for Alzheimer's disease , 2002 .

[60]  D. A. Bennett,et al.  Natural history of mild cognitive impairment in older persons , 2002, Neurology.

[61]  W. Markesbery,et al.  Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: Findings from the Nun Study , 2002, Annals of neurology.

[62]  J. Wands,et al.  The AD7c-NTP neuronal thread protein biomarker for detecting Alzheimer's disease. , 2002, Journal of Alzheimer's disease : JAD.

[63]  B. Oken.  Practice parameter: Management of dementia (an evidence-based review) , 2001, Neurology.

[64]  J. Morris,et al.  Current concepts in mild cognitive impairment. , 2001, Archives of neurology.

[65]  Rong Wang,et al.  A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity , 2001, Nature.

[66]  G. Alexander,et al.  Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. , 2001, JAMA.

[67]  E. Topol,et al.  Risk of cardiovascular events associated with selective COX-2 inhibitors. , 2001, JAMA.

[68]  Nick C Fox,et al.  Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images , 2001, The Lancet.

[69]  J. Cummings,et al.  Alzheimer's Disease and Related Disorders Annual - 2001 , 2001 .

[70]  E. Tangalos,et al.  CME Practice parameter: , 2022 .

[71]  R. S. Doody, MD, PhD,et al.  Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .

[72]  B. Miller,et al.  CME Practice parameter : Diagnosis of dementia ( an evidence-based review ) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .

[73]  J. Price,et al.  Mild cognitive impairment represents early-stage Alzheimer disease. , 2001, Archives of neurology.

[74]  J. Touchon,et al.  Classification criteria for mild cognitive impairment , 2001, Neurology.

[75]  Karen Ritchie,et al.  Classification criteria for mild cognitive impairment: A population-based validation study , 2001 .

[76]  D. Selkoe.  The genetics and molecular pathology of Alzheimer's disease: roles of amyloid and the presenilins. , 2000, Neurologic clinics.

[77]  R. Petersen,et al.  Aging, mild cognitive impairment, and Alzheimer's disease. , 2000, Neurologic clinics.

[78]  J. Cummings,et al.  Neurobehavioral and neuropsychiatric symptoms in Alzheimer's disease: characteristics and treatment. , 2000, Neurologic clinics.

[79]  W. Kukull,et al.  Epidemiology of dementia: concepts and overview. , 2000, Neurologic clinics.

[80]  H J Koch,et al.  A randomized controlled trial of prednisone in Alzheimer’s disease , 2000, Neurology.

[81]  R. Tamura,et al.  Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. , 2000, Archives of general psychiatry.

[82]  E G Tangalos,et al.  Regional metabolic patterns in mild cognitive impairment and Alzheimer’s disease , 2000, Neurology.

[83]  P. Tariot,et al.  A 5-month, randomized, placebo-controlled trial of galantamine in AD , 2000, Neurology.

[84]  F. D. Miller,et al.  Functional gamma‐secretase inhibitors reduce beta‐amyloid peptide levels in brain , 2000, Journal of neurochemistry.

[85]  C. Jack,et al.  Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD , 2000, Neurology.

[86]  R. Peterson,et al.  Mild cognitive impairment: Transition from aging to Alzheimer's disease , 2000, Neurobiology of Aging.

[87]  D. Zaitchik,et al.  Predicting conversion to Alzheimer disease using standardized clinical information. , 2000, Archives of neurology.

[88]  J. Cummings,et al.  Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. , 2000, The Journal of neuropsychiatry and clinical neurosciences.

[89]  R. Killiany,et al.  Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease , 2000, Annals of neurology.

[90]  R. Petersen,et al.  Mild cognitive impairment: transition between aging and Alzheimer's disease. , 2000, Neurologia.

[91]  Anthony Gamst,et al.  Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial , 2000 .

[92]  K. Davis,et al.  A randomized controlled trial of prednisone in Alzheimer’s disease , 2000, Neurology.

[93]  B L Miller,et al.  Estrogen for Alzheimer’s disease in women , 2000, Neurology.

[94]  R. Barbour,et al.  Purification and cloning of amyloid precursor protein β-secretase from human brain , 1999, Nature.

[95]  Alfredo G. Tomasselli,et al.  Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity , 1999, Nature.

[96]  David G. Tew,et al.  Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase , 1999, Molecular and Cellular Neuroscience.

[97]  K. Blennow,et al.  Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. , 1999, Neurology.

[98]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[99]  T. Lehtimäki,et al.  Longitudinal stability of CSF tau levels in Alzheimer patients , 1999, Biological Psychiatry.

[100]  P. Aisen,et al.  Regional distribution of cyclooxygenase‐2 in the hippocampal formation in Alzheimer's disease , 1999, Journal of neuroscience research.

[101]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[102]  Šimon Scharf,et al.  A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease , 1999, Neurology.

[103]  K. Blennow,et al.  Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. , 1999, Archives of neurology.

[104]  P. Deyn,et al.  Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF , 1999, Neurology.

[105]  D. Q. Mcmanus,et al.  Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group. , 1999, The Journal of clinical psychiatry.

[106]  C. Jack,et al.  Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment , 1999, Neurology.

[107]  P Dal-Bianco,et al.  Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. , 1999, BMJ.

[108]  Y. Agid,et al.  Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trialCommentary: Another piece of the Alzheimer's jigsaw , 1999 .

[109]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[110]  D. Jeste,et al.  Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. , 1999, The Journal of clinical psychiatry.

[111]  A. Kurz,et al.  Tau Protein in Cerebrospinal Fluid Is Significantly Increased at the Earliest Clinical Stage of Alzheimer Disease , 1998, Alzheimer disease and associated disorders.

[112]  J. Hardy,et al.  Genetic classification of primary neurodegenerative disease. , 1998, Science.

[113]  K. Ishii,et al.  Cerebral glucose metabolism in patients with frontotemporal dementia. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[114]  R Brookmeyer,et al.  Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. , 1998, American journal of public health.

[115]  L. Beckett,et al.  Vitamin E and Vitamin C Supplement Use and Risk of Incident Alzheimer Disease , 1998, Alzheimer disease and associated disorders.

[116]  N. Delanty,et al.  Risk of Alzheimer's disease and duration of NSAID use , 1998, Neurology.

[117]  P. Aisen,et al.  Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain , 1998, Neuroscience.

[118]  J. Kaye,et al.  High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. , 1998, Archives of neurology.

[119]  S. Hirai,et al.  Combination assay of CSF Tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer's disease , 1998, Journal of the Neurological Sciences.

[120]  H J Testa,et al.  A clinical role for 99mTc-HMPAO SPECT in the investigation of dementia? , 1998, Journal of neurology, neurosurgery, and psychiatry.

[121]  A D Roses,et al.  Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. , 1998, The New England journal of medicine.

[122]  H. Ghanbari,et al.  Characterization of the AD7C-NTP cDNA expression in Alzheimer's disease and measurement of a 41-kD protein in cerebrospinal fluid. , 1997, The Journal of clinical investigation.

[123]  D. Sultzer,et al.  A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. , 1997, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[124]  R. Brookmeyer,et al.  A prospective study of estrogen replacement therapy and the risk of developing Alzheimer''s disease , 1997 .

[125]  J. Haines,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.

[126]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[127]  J. Trojanowski,et al.  Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease , 1997, Journal of neuropathology and experimental neurology.

[128]  P. Tariot,et al.  An open trial of valproate for agitation in geriatric neuropsychiatric disorders. , 1997, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[129]  C. Jack,et al.  Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease , 1997, Neurology.

[130]  S Minoshima,et al.  Quantitative assessment of cerebral blood flow in patients with Alzheimer's disease by SPECT. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[131]  John Q. Trojanowski,et al.  Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease , 1997, Neurobiology of Aging.

[132]  S. Shumaker,et al.  Hormone replacement therapy and other potential treatments for dementias. , 1997, Endocrinology and metabolism clinics of North America.

[133]  J. Goeman,et al.  Discriminative use of SPECT in frontal lobe-type dementia versus (senile) dementia of the Alzheimer's type. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[134]  H. Stähelin,et al.  The Relation Between Antioxidants and Memory Performance in the Old and Very Old , 1997, Journal of the American Geriatrics Society.

[135]  S. Borson,et al.  Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer's disease , 1997, Neurology.

[136]  P Woodbury,et al.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.

[137]  M. Albert,et al.  The course of psychopathologic features in mild to moderate Alzheimer disease. , 1997, Archives of general psychiatry.

[138]  D. Galasko,et al.  Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease , 1997, Neurology.

[139]  A. Hofman,et al.  Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study , 1997, The Lancet.

[140]  R. Rosenberg.  The Molecular and Genetic Basis of Neurological Disease , 1997 .

[141]  Nick C Fox,et al.  Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. , 1996, Brain : a journal of neurology.

[142]  V. Henderson,et al.  Estrogen replacement therapy and risk of Alzheimer disease. , 1996, Archives of internal medicine.

[143]  Cohen-Mansfield,et al.  Agitation: Subtypes and Their Mechanisms. , 1996, Seminars in clinical neuropsychiatry.

[144]  D J Foley,et al.  Prevalence of dementia in older Japanese-American men in Hawaii: The Honolulu-Asia Aging Study. , 1996, JAMA.

[145]  Yaakov Stern,et al.  Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease , 1996, The Lancet.

[146]  H. Buschke,et al.  The effects of preclinical dementia on estimates of normal cognitive functioning in aging. , 1996, The journals of gerontology. Series B, Psychological sciences and social sciences.

[147]  Ronald C. Petersen,et al.  Definition, course, and outcome of mild cognitive impairment , 1996 .

[148]  S. Thibodeau,et al.  Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. , 1996, The New England journal of medicine.

[149]  C. Martyn,et al.  Cognitive impairment and mortality in a cohort of elderly people , 1996, BMJ.

[150]  R. Mayeux,et al.  Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community. , 1996, Archives of general psychiatry.

[151]  C. Ballard,et al.  The prevalence, associations and symptoms of depression amongst dementia sufferers. , 1996, Journal of affective disorders.

[152]  Jeffrey L. Cummings,et al.  The spectrum of behavioral changes in Alzheimer's disease , 1996, Neurology.

[153]  W. Snow,et al.  A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment , 1996, Neurology.

[154]  K. Fleming,et al.  Dementia: diagnosis and evaluation. , 1995, Mayo Clinic proceedings.

[155]  I. Mena,et al.  SPECT in Dementia: Clinical and Pathological Correlation , 1995, Journal of the American Geriatrics Society.

[156]  H C Hendrie,et al.  Prevalence of Alzheimer's disease and dementia in two communities: Nigerian Africans and African Americans. , 1995, The American journal of psychiatry.

[157]  A. Hofman,et al.  Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? , 1995, Neurology.

[158]  M. Pericak-Vance,et al.  Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs , 1995, Neurobiology of Aging.

[159]  G. Walstra,et al.  Diagnosing Alzheimer's disease in elderly, mildly demented patients: the impact of routine single photon emission computed tomography , 1995, Journal of Neurology.

[160]  A D Roses,et al.  Apolipoprotein E and Alzheimer disease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[161]  D. Schaid,et al.  Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. , 1995, JAMA.

[162]  J C Mazziotta,et al.  Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. , 1995, JAMA.

[163]  M. Albert,et al.  Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease , 1994, Neurology.

[164]  KennethRockwood,et al.  The Canadian Study of Health and Aging* , 1994, Neurology.

[165]  J. Buckwalter,et al.  Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects. , 1994, Archives of neurology.

[166]  V. Henderson,et al.  Estrogen deficiency and risk of Alzheimer's disease in women. , 1994, American journal of epidemiology.

[167]  K. Davis,et al.  Inflammatory mechanisms in Alzheimer's disease: implications for therapy. , 1994, The American journal of psychiatry.

[168]  E. P. Krenning,et al.  The diagnostic value of SPECT with Tc 99m HMPAO in Alzheimer's disease , 1994, Neurology.

[169]  W. McDonald,et al.  Inverse association of anti‐inflammatory treatments and Alzheimer's disease , 1994, Neurology.

[170]  M F Kijewski,et al.  Quantitative brain SPECT in Alzheimer's disease and normal aging. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[171]  A. Kaszniak,et al.  Clinical trial of indomethacin in Alzheimer's disease , 1993, Neurology.

[172]  J. Rabe-Jabłońska,et al.  [Affective disorders in the fourth edition of the classification of mental disorders prepared by the American Psychiatric Association -- diagnostic and statistical manual of mental disorders]. , 1993, Psychiatria polska.

[173]  S. Hauser,et al.  Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimer's disease , 1992, Annals of neurology.

[174]  J. Rogers,et al.  Anti‐inflammatory agents as a therapeutic approach to Alzheimer's disease , 1992, Neurology.

[175]  R. D'Agostino,et al.  Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study , 1992, Neurology.

[176]  M. Folstein,et al.  Psychosis and physical aggression in probable Alzheimer's disease. , 1991, The American journal of psychiatry.

[177]  E. Tangalos,et al.  The short test of mental status. Correlations with standardized psychometric testing. , 1991, Archives of neurology.

[178]  G. Zubenko,et al.  Emergence of psychosis and depression in the longitudinal evaluation of Alzheimer's disease , 1991, Biological Psychiatry.

[179]  R. Lévy,et al.  Psychiatric Phenomena in Alzheimer's Disease. IV: Disorders of Behaviour , 1990, British Journal of Psychiatry.

[180]  A. Burns,et al.  Psychiatric Phenomena in Alzheimer's Disease. III: Disorders of Mood , 1990, British Journal of Psychiatry.

[181]  J. Growdon,et al.  Iofetamine I 123 single photon emission computed tomography is accurate in the diagnosis of Alzheimer's disease. , 1990, Archives of internal medicine.

[182]  D. Mungas,et al.  PSYCHOTIC SYMPTOMS IN ALZHEIMER'S DISEASE , 1989, The Lancet.

[183]  M. Albert,et al.  Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. , 1989, JAMA.

[184]  K P Offord,et al.  Prevalence of medically diagnosed dementia in a defined United States population , 1989, Neurology.

[185]  D. Knopman,et al.  A verbal memory test with high predictive accuracy for dementia of the Alzheimer type. , 1989, Archives of neurology.

[186]  Wayne C. Drevets,et al.  Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type , 1989, Biological Psychiatry.

[187]  E B Larson,et al.  Behavioral Disturbance in Dementia of the Alzheimer's Type , 1988, Journal of the American Geriatrics Society.

[188]  W. Drevets,et al.  The Nature of Psychotic Symptoms in Senile Dementia of the Alzheimer Type , 1988, Journal of geriatric psychiatry and neurology.

[189]  H. Chui,et al.  The Modified Mini-Mental State (3MS) examination. , 1987, The Journal of clinical psychiatry.

[190]  S H Ferris,et al.  Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. , 1987, The Journal of clinical psychiatry.

[191]  C. Mulrow,et al.  The Role of Lumbar Puncture in the Evaluation of Dementia: The Durham Veterans Administration/Duke University Study , 1985, Journal of the American Geriatrics Society.

[192]  R. Katzman.,et al.  Validation of a short Orientation-Memory-Concentration Test of cognitive impairment. , 1983, The American journal of psychiatry.

[193]  J. Coyle,et al.  Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis , 1981, Annals of neurology.

[194]  R. Petersen,et al.  Scopolamine induced learning failures in man , 1977, Psychopharmacology.

[195]  P. Davies,et al.  SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE , 1976, The Lancet.

[196]  D M Bowen,et al.  Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. , 1976, Brain : a journal of neurology.

[197]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[198]  P. Tariot,et al.  Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. , 2006, Neurology.

[199]  D. Allison,et al.  Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. , 2005, Archives of general psychiatry.

[200]  S. Wagner,et al.  Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897. , 2005, Biochemical pharmacology.

[201]  P. Scheltens,et al.  Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. , 2004, Neurology.

[202]  S. Weggen,et al.  Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. , 2003, The Journal of biological chemistry.

[203]  L. Launer.  Nonsteroidal anti-inflammatory drug use and the risk for Alzheimer's disease: dissecting the epidemiological evidence. , 2003, Drugs.

[204]  Pritam Das,et al.  NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. , 2003, The Journal of clinical investigation.

[205]  G. Small,et al.  Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[206]  B. Winblad,et al.  Alzheimer's disease : advances in etiology, pathogenesis, and therapeutics , 2001 .

[207]  A. Roses,et al.  Apolipoprotein E and Alzheimer's disease. , 1996, Annual review of neuroscience.

[208]  J. Cummings,et al.  Alzheimer's disease and related disorders annual , 2000 .

[209]  E. Tangalos,et al.  Testing normal older people three or four times at 1- to 2-year intervals: defining normal variance. , 1999, Neuropsychology.

[210]  C. Southan,et al.  Identification of a novel aspartic protease (Asp 2) as beta-secretase. , 1999, Molecular and cellular neurosciences.

[211]  H. Ghanbari,et al.  A sandwich enzyme immunoassay for measuring AD7C‐NTP as an Alzheimer's disease marker: AD7C test , 1998, Journal of clinical laboratory analysis.

[212]  R Mielke,et al.  Positron emission tomography for diagnosis of Alzheimer's disease and vascular dementia. , 1998, Journal of neural transmission. Supplementum.

[213]  P. Tariot,et al.  Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. , 1998, The American journal of psychiatry.

[214]  B. Dastugue,et al.  [Apolipoprotein E and Alzheimer's disease]. , 1998, Annales de biologie clinique.

[215]  S. Hirai,et al.  Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease. , 1998, Journal of the neurological sciences.

[216]  H. Arai,et al.  Apolipoprotein E genotyping and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimer's disease. , 1997, Gerontology.

[217]  K. Haaland,et al.  Nutritional status and cognitive functioning in a normally aging sample: a 6-y reassessment. , 1997, The American journal of clinical nutrition.

[218]  K. Iqbal,et al.  Alzheimer's disease : biology, diagnosis, and therapeutics , 1996 .

[219]  K. Fleming,et al.  Dementia : diagnosis and evaluation : Geriatrics. V , 1995 .

[220]  Canadian study of health and aging: study methods and prevalence of dementia. , 1994, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[221]  E. Tangalos,et al.  Mayo's older americans normative studies: WAIS-R norms for ages 56 to 97 , 1992 .

[222]  James F. Malec,et al.  Mayo's older americans normative studies: Updated AVLT norms for ages 56 to 97 , 1992 .

[223]  J. Goodwin,et al.  Association between nutritional status and cognitive functioning in a healthy elderly population. , 1983, JAMA.

[224]  A. Lbert,et al.  Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease , 2022 .